Core Viewpoint - WuXi Biologics reported record annual results for 2025, showcasing significant growth across various financial metrics, driven by strategic execution and increasing demand for complex biologics [1][19]. Financial Highlights - Revenue increased by 16.7% year-over-year (YoY) to RMB 21.8 billion, supported by the "Follow and Win the Molecule" strategy and rising demand for complex biologics [2][6]. - Gross profit rose by 30.9% YoY to RMB 10.0 billion, with gross margin expanding by 500 basis points to 46.0% [3][6]. - EBITDA grew by 38.1% YoY to RMB 9.0 billion, with an EBITDA margin of 41.5% [4][6]. - Net profit increased by 45.3% YoY to RMB 5.7 billion, driven by higher gross profits and gains from the investment portfolio [5][6]. Business Highlights - A record 209 new integrated projects were signed in 2025, bringing the total to 945, with strong contributions from U.S. clients [8][21]. - Research Services generated record-high payments, securing potential milestone and royalties exceeding US$4 billion [9][10]. - The Group supported 156 IND filings in 2025, expanding capacity to 200 INDs and 20 BLAs/MAAs annually [10][11]. Development and Manufacturing - Bispecifics and ADCs accounted for two-thirds of new project additions, reflecting a 30% growth in each modality [10][11]. - The Group maintained a 100% success rate in process performance qualifications (PPQs) and has 34 PPQs scheduled for 2026 [12][21]. - Total backlog reached US$23.7 billion, with US$4.5 billion expected within three years, indicating strong near-term revenue visibility [14][21]. Quality and Compliance - The Group has completed 46 regulatory inspections with no critical issues, maintaining a 100% pass rate for FDA Pre-License Inspections [15][19]. - The company has passed over 1,800 client GMP audits, demonstrating consistent quality and compliance standards [15][19]. Talent and Operational Efficiency - The workforce comprised 13,252 employees, including 4,885 scientists, with a talent retention rate of 96.4% [15][19]. - The WuXi Biologics Business System (WBS) contributed to gross margin improvement through over 430 Kaizen initiatives [16][19]. Sustainability and ESG - WuXi Biologics has been recognized for its ESG practices, achieving high ratings from global ESG rating agencies and inclusion in the Dow Jones Sustainability Indices [18][26].

Core Insights - Curia announced the progress of its sterile drug manufacturing facility expansion in Glasgow, UK, which is expected to be completed by early 2027 [1] - The expansion will add a new isolator-based vial filling line and a lyophilizer, increasing the filling capacity to a maximum of 20,000 vials per batch [1] - Curia's improvements to its cell line development (CLD) platform will enhance its clinical active pharmaceutical ingredient development capabilities [1] Group 1: Facility Expansion - The Glasgow facility has over 25 years of experience in formulation, lyophilization development, and sterile filling, making it well-regarded in the industry [1] - The expansion is designed to support future small-scale commercial filling needs and will not disrupt existing operations during the construction phase [1] Group 2: Technology Advancements - Curia's CLD platform has been upgraded with a non-IP restrictive semi-targeted integration technology, resulting in a sixfold increase in titer compared to random integration technology [1] - The stable platform CHO-GSN® and the transient expression platform TunaCHO® are derived from the same parent cell line, facilitating efficient scale-up from R&D to GMP-compliant production [1][2] Group 3: Company Overview - Curia is a contract research, development, and manufacturing organization (CDMO) with over 30 years of experience and a global network of facilities [2] - The company employs over 3,100 people and collaborates with biopharmaceutical clients to bring life-changing therapies to market [2]

Core Insights - WuXi Biologics has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, achieving a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, ranking first in its industry [1][1][1] Group 1: Company Performance - The company was recognized among 848 top performers out of over 9,200 companies assessed in the 2025 CSA [1][1] - WuXi Biologics' CEO, Dr. Chris Chen, emphasized the company's commitment to enhancing sustainability performance and delivering ESG excellence [1][1] Group 2: Sustainability Initiatives - WuXi Biologics is a participant in the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), advocating for sustainability [1][1] - The company has received multiple recognitions, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices [1][1][1] Group 3: Operational Overview - WuXi Biologics employs over 12,000 skilled employees across various countries and supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [1][1] - The company aims to become an ESG leader in the biologics CRDMO sector, utilizing next-generation biomanufacturing technologies and clean-energy sources [1][1]

Core Viewpoint - ICON Public Limited Company (NASDAQ:ICLR) is a significant player in the Contract Research Organization (CRO) sector, providing a wide range of outsourced development services to the pharmaceutical, biotechnology, and medical device industries [1] Financial Performance and Guidance - ICLR's management has reaffirmed its full-year 2025 guidance, expecting revenue between $8.05 billion and $8.1 billion, with adjusted earnings per share (EPS) guidance of $13.00 to $13.20 [3][5] - The stock price of ICLR is currently at $99.70, reflecting a slight increase of 1.29, or 1.31% [4] Market Activity and Stock Performance - ICLR's stock has shown significant volatility over the past year, with a high of $211 and a low of $66.57 [4] - The trading volume for ICLR on the NASDAQ exchange stands at 1,642,937 shares, indicating active investor interest [4] Analyst Insights - Jefferies analyst David Windley has set a price target of $135 for ICLR, suggesting a potential increase of approximately 35.41% from its current price [2][5] - Despite recent challenges, including a significant stock price decline, the optimistic outlook from analysts indicates confidence in the company's recovery [2][5] Legal and Regulatory Issues - Levi & Korsinsky has initiated an investigation into ICLR for potential violations of federal securities laws following a notable decline in stock price that erased billions in shareholder value [2][5]

Core Insights - Sai Life Sciences Limited released its Sustainability Report for 2024–25, focusing on "Driving climate action, deepening stakeholder trust" and aligning with GRI and SASB standards [1][2] Sustainability Strategy - The company's sustainability strategy is based on nine strategic pillars: water stewardship, climate action, circularity, biodiversity, sustainable procurement, human capital, governance and ethics, community engagement, and customer co-creation [2][3] - These pillars integrate sustainability into all operational stages, aligning with business objectives and stakeholder expectations [2] Sustainable Development Goals - Sai Life Sciences has defined Sustainable Development Goals (SDGs) to meet its sustainability commitments by March 31, 2027, with ongoing progress in greenhouse gas reduction and renewable energy usage [3][4] - The API manufacturing unit in Bidar is powered by 96% renewable energy, and the company has reduced specific water consumption across its facilities [3] Community Impact - The company exceeded its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities, demonstrating significant community impact [3] Workforce Diversity - The organization has seen steady growth in diversity, with women representing 14% of the workforce [3] Long-term Vision - The 2024–25 Sustainability Report reflects the company's long-term view, emphasizing science, responsibility, and collaboration as central to its growth ambitions [4]

Core Insights - WuXi Biologics has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to expand its global network and capabilities into the Middle East [1][3]. Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for the discovery, development, and manufacturing of biologics [5][6]. - The company employs over 12,000 skilled professionals across various countries, including China, the United States, Ireland, Germany, and Singapore [6]. Strategic Collaboration - The MoU facilitates the establishment of WuXi Biologics' first integrated CRDMO center in the Middle East, aiming to enhance Qatar's biotechnology sector and create a robust biopharmaceutical ecosystem [3][4]. - This partnership combines WuXi Biologics' expertise in complex biologics with Qatar's strategic vision for biopharmaceutical advancement, fostering innovation and growth [3][4]. Leadership Statements - Dr. Chris Chen, CEO of WuXi Biologics, emphasized that this partnership marks a significant step in extending the company's global capabilities and contributing to the biopharmaceutical ecosystem in Qatar [4]. - H.E. Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani, CEO of QFZ, highlighted that the collaboration strengthens Qatar's position as a reliable hub for biopharmaceutical growth, leveraging WuXi Biologics' global expertise [4]. Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone of its long-term growth strategy, focusing on green technology innovations and responsible practices across its operations [8].

Core Insights - Madison Mid Cap Fund's Class I returned 1.9% in Q3 2025, underperforming the Russell Midcap Index which increased by 5.3% [1] - Information Technology was the leading sector in performance for both the quarter and year-to-date [1] Company Performance - Medpace Holdings, Inc. (NASDAQ:MEDP) had a one-month return of -3.15% but gained 73.55% over the last 52 weeks, closing at $586.16 per share with a market capitalization of $17.047 billion on November 20, 2025 [2] - Medpace reported revenue of $659.9 million in Q3 2025, marking a year-over-year increase of 23.7% [4] Investment Insights - Medpace was one of the top five contributors to the Madison Mid Cap Fund's performance in Q3 2025, with shares rising due to better-than-expected Q2 results and strong revenue and bookings growth [3] - Despite the potential of Medpace as an investment, the company is not among the 30 most popular stocks among hedge funds, with 42 hedge fund portfolios holding its shares at the end of Q2 2025, unchanged from the previous quarter [4]

Core Insights - WuXi AppTec has been awarded the 2025 Global Company of the Year Award in the CRDMO industry by Frost & Sullivan, marking the ninth consecutive year of receiving this honor, which highlights the company's achievements in innovation and operational excellence [1][4] Company Overview - WuXi AppTec operates as a leading global pharmaceutical CRDMO, providing integrated, end-to-end services that drive scientific and technological advancement, enabling faster drug development and delivery of transformative therapies [2][5] - The company has established a robust foundation of scientific capability, quality, and customer-focused agility through a forward-looking growth strategy, which includes continuous investment in next-generation technologies such as complex peptides, oligonucleotides, and novel conjugates [3][5] Strategic Partnerships and Market Position - The integrated CRDMO model of WuXi AppTec eliminates handoffs between development stages, supporting continuity, quality, and compliance across the value chain, which helps clients reduce risk and improve efficiency [3][4] - The company serves a diverse range of clients, from emerging biotech firms to pharmaceutical multinationals, ensuring fast access to specialized expertise and a global infrastructure [3][5] Leadership and Future Focus - Dr. Ge Li, Chairman and CEO of WuXi AppTec, emphasized the commitment of the global teams to enable customers to advance medicines through the integrated CRDMO platform, with a focus on expanding global capabilities and capacity [4] - Frost & Sullivan's recognition is based on outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning [4]

Core Insights - IQVIA Holdings Inc. is valued at $37.6 billion and provides healthcare research services, including analytics, technology solutions, and clinical research to the life sciences industry, aimed at improving healthcare outcomes for patients [1] Performance Overview - Over the past year, IQV shares have gained 12.2%, underperforming the S&P 500 Index, which increased by nearly 13.7% [2] - In 2025, IQV's stock rose 10%, while the S&P 500 saw a 13.4% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7% over the past year, IQV's performance is relatively better, although the ETF's 10.3% year-to-date returns outshine IQV's gains [3] Financial Results - For Q3, IQV reported an adjusted EPS of $3, exceeding Wall Street expectations of $2.96, and revenue of $4.10 billion, beating forecasts of $4.07 billion [4] - The company expects full-year adjusted EPS to be in the range of $11.85 to $11.95 and revenue between $16.2 billion and $16.3 billion [4] Analyst Expectations - Analysts project IQV's EPS to grow by 5.1% to $10.77 for the current fiscal year ending in December [5] - Among 22 analysts covering IQV, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [5] - A month ago, the bullish sentiment increased, with 15 analysts suggesting a "Strong Buy" [6] Price Targets - BMO Capital initiated coverage of IQV with an "Outperform" rating and a price target of $260, indicating a potential upside of 20.3% from current levels [6] - The mean price target is $244.38, representing a 13.1% premium to current prices, while the highest price target of $265 suggests an upside potential of 22.6% [6]

Core Insights - U.S. stocks experienced a rally in Q3, supported by the Federal Reserve's interest rate cut and steady economic data, with the Russell Midcap® Growth Index increasing by 2.78% [3][17] - The Wasatch U.S. Select Fund underperformed, declining by -1.93%, primarily due to concentrated holdings in stocks that faced slower revenue growth [3][4][17] Fund Performance Analysis - The Fund's performance was negatively impacted by a few concentrated stock holdings that reported slower revenue growth, leading to significant declines in their stock prices [4][6] - The investment strategy focuses on high-quality, long-duration growth companies, which faced headwinds as low-quality stocks gained favor in the market [7] Key Detractors - BellRing Brands, Inc. (BRBR) was the largest detractor, with concerns over competition in the protein shake category; however, the long-term outlook remains positive due to category growth potential [8] - Shift4 Payments, Inc. (FOUR) faced stock price declines despite solid organic revenue growth, attributed to macroeconomic concerns and investor sentiment following its acquisition of Global Blue [9] - Inspire Medical Systems, Inc. (INSP) was sold during the quarter after management downgraded guidance due to delays in product rollout, raising execution concerns [10] Top Contributors - Medpace Holdings, Inc. (MEDP) was the top contributor, with strong revenue and earnings growth, raising full-year guidance despite a slowdown in biotech funding [11] - Fabrinet (FN) benefited from strong product adoption, particularly in data centers linked to AI, although the investment is not solely based on AI themes [12] - Nova Ltd. (NVMI) also contributed positively, with a strong track record in semiconductor manufacturing, benefiting from increasing complexity in the industry [13] Future Outlook - The Fund remains committed to its investment philosophy, focusing on high-quality growth companies despite recent underperformance [14] - The fundamentals of the companies within the Fund are encouraging, with strong earnings growth expected to drive return potential over a three- to five-year horizon [15]